News!!https://apple.news/AiU_UGIvvTkK3Em8vr7_kJQWINNIPEG, MB, Jan. 18, 2021 /CNW/ - Waverley Pharma Inc. (TSXV: WAVE) ("Waverley Pharma" or the "Company"), an emerging Canadian pharmaceutical company, is pleased to announce that its wholly owned Irish subsidiary, Waverley Pharma Europe Limited ("WPEL"), has been awarded exclusive distribution rights for capecitabine by the National Health Services of Scotland ("NHS Scotland"). The awarded NHS Scotland tender is projected to increase the Company's revenue by approximately £200,000 on an annual basis. This opportunity also represents WPEL's first successful tender proposal for capecitabine in the NHS Scotland region. The tender will commence on February 1, 2021 and has a duration of two years. WPEL currently has awarded tenders for capecitabine in both Wales and England with each region's respective National Health Services organization.
"Waverley Pharma is excited to announce our fifth successful tender award since 2019, which affirms our commitment to expanding our oncology presence in the UK and EU markets," stated Larry Thiessen, President and Chief Executive Officer.